ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.98
+0.64 (3.00%)
At close: Jun 6, 2025, 4:00 PM
21.75
-0.23 (-1.05%)
After-hours: Jun 6, 2025, 5:06 PM EDT
ACADIA Pharmaceuticals Revenue
ACADIA Pharmaceuticals had revenue of $244.32M in the quarter ending March 31, 2025, with 18.70% growth. This brings the company's revenue in the last twelve months to $996.28M, up 22.42% year-over-year. In the year 2024, ACADIA Pharmaceuticals had annual revenue of $957.80M with 31.85% growth.
Revenue (ttm)
$996.28M
Revenue Growth
+22.42%
P/S Ratio
3.67
Revenue / Employee
$1,523,369
Employees
654
Market Cap
3.68B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACAD News
- 1 day ago - Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025 - Business Wire
- 8 days ago - Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire
- 10 days ago - Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise - Business Wire
- 17 days ago - Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 18 days ago - These Analysts Boost Their Forecasts On Acadia Pharmaceuticals - Benzinga
- 20 days ago - Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview - Seeking Alpha
- 21 days ago - Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation - Business Wire
- 24 days ago - ACADIA Pharmaceuticals: Advancing On Several Fronts - Seeking Alpha